Fierce Biotech1 min read
saveGenerate Biomedicines CEO touts AI-driven shrinkage of CAR-T cell engines as huge opportunity
read at Fierce Biotech ↗Positive
Generate Biomedicines' chief executive highlighted a "huge opportunity" after the company applied Anthropic's Claude AI platform to make its CAR‑T cell engines smaller.
The Flagship‑founded biotech used the Claude system to streamline the genetic constructs that power CAR‑T therapies, achieving a reduction in size that could simplify manufacturing and delivery.
The CEO suggested that the AI‑enabled approach may accelerate development timelines and lower costs, positioning the firm to advance its cell therapy pipeline more efficiently.
source
This writeup was produced by pharmadog from original reporting by Fierce Biotech.
Original headline: “Generate CEO sees ‘huge opportunity’ from using Claude to shorten CAR-T cell engines”
read at Fierce Biotech ↗
comments(0)
5-min edit window · permanent after that